a166
mAbexperimentalADC
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jul 16, 2018 (NCT03602079)
Timeline
Indications
Studied for
- Bile Duct Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 3
- Carcinoma, Mucoepidermoid · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Cholangiocarcinoma · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Genes, erbB-2 · Phase 1/Phase 2
- Hamartoma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Laryngeal Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Mouth Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1/Phase 2
- Rare Diseases · Phase 1/Phase 2
- Rectal Neoplasms · Phase 1/Phase 2
- Salivary Gland Neoplasms · Phase 1/Phase 2
- Skin Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Tongue Neoplasms · Phase 1/Phase 2
- Tonsillar Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
- Urologic Neoplasms · Phase 1/Phase 2
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- emtansine
Oral
No
Parenteral
No
Topical
No
Also known as
- a166
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07299825 | Phase 2 | Sep 20, 2024 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT06968585 | Phase 3 | Jul 18, 2023 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT05346328 | Phase 2 | Jun 1, 2022 | Fudan University |
| NCT05311397 | Phase 1 | Aug 9, 2018 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT03602079 | Phase 1/Phase 2 (Phase 2) | Jul 16, 2018 | Klus Pharma Inc., University of Texas at Houston |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 3 | 3 | 3 | 2018 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Klus Pharma Inc. | For profit | 1 | 1 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1